Osteoporosis Pharmacotherapy: Romosozumab, Denosumab, and Sequential Therapy Strategy
Romosozumab: Anti-Sclerostin Dual Mechanism
Romosozumab (210 mg SC monthly for 12 months) is a monoclonal antibody against sclerostin that uniquely increases bone formation while simultaneously decreasing bone resorption. The FRAME trial demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months (0.5% vs 1.8%, p<0.001). The ARCH trial, comparing romosozumab to alendronate, showed a 48% reduction in new vertebral fractures at 12 months (4.0% vs 7.5%) with romosozumab followed by alendronate. BMD gains at the lumbar spine are approximately 13% at 12 months, the largest increase seen with any osteoporosis therapy.
Cardiovascular Safety Signal
The ARCH trial identified a cardiovascular safety signal with romosozumab versus alendronate (2.5% vs 1.9% adjudicated serious cardiovascular events at 12 months). This led to a boxed warning contraindicating romosozumab in patients with MI or stroke within the preceding year. The FRAME trial (romosozumab vs placebo) did not show this imbalance. Current guidance restricts romosozumab to patients at very high fracture risk without recent cardiovascular events, requiring individualized risk-benefit discussion.
Denosumab: Efficacy and the Rebound Problem
Denosumab (60 mg SC every 6 months) reduced hip fracture by 40%, vertebral fracture by 68%, and nonvertebral fracture by 20% over 3 years in the FREEDOM trial. Ten-year extension data showed continued BMD gains and sustained fracture risk reduction. However, denosumab discontinuation triggers rapid bone loss (returning to pre-treatment BMD within 12-18 months) with a documented rebound vertebral fracture risk. Multiple case series report multiple vertebral fractures within 7-18 months of discontinuation. Current guidelines mandate transition to a bisphosphonate (zoledronic acid 5 mg IV preferred) upon denosumab cessation, timed to coincide with the next scheduled denosumab dose.
Sponsored
Sequential Therapy: The Anabolic-First Strategy
The treat-to-target approach recommends anabolic therapy first in very high-risk patients (T-score ≤-3.0, recent fracture, multiple fractures, fracture on antiresorptive therapy). The DATA-Switch study demonstrated that teriparatide followed by denosumab produced greater BMD gains than the reverse sequence. Similarly, romosozumab for 12 months followed by denosumab or a bisphosphonate consolidates anabolic gains. Starting with an antiresorptive and switching to an anabolic agent produces a blunted BMD response, supporting the anabolic-first paradigm.
Practical Sequencing for Clinical Practice
For very high fracture risk: romosozumab 12 months then transition to denosumab or zoledronic acid. For high fracture risk: teriparatide or abaloparatide for 18-24 months then bisphosphonate. For moderate fracture risk: oral bisphosphonate (alendronate 70 mg weekly or risedronate 150 mg monthly) as initial therapy. Zoledronic acid 5 mg IV annually is preferred for adherence-challenged patients. Treatment duration follows the bisphosphonate drug holiday concept: reassess after 5 years of oral bisphosphonate or 3 years of IV zoledronic acid, with continuation in high-risk patients and a drug holiday of 2-3 years in moderate-risk patients with stable BMD.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.